Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationAngiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Self-citationSoker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M., Isner, J. M., & Asahara, T. (1999) · Nature Medicine · doi:10.1038/7434 · Cited by 2,423
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“In December 2004, the FDA approved pegaptinib, an aptamer that blocks the 165 amino-acid isoform of VEGF-A, for the treatment of the wet (neovascular) form of age-related macular degeneration (AMD”
BackgroundPericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice
Lindahl, P., Johansson, B. R., Levéen, P., & Betsholtz, C. (1997) · Science · doi:10.1126/science.277.5323.242 · Cited by 2,226
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 1×
“reported that a single infusion of bevacizumab to patients with rectal carcinoma rapidly decreased tumour perfusion, vascular volume, microvascular density and interstitial fluid pressure as well as the number of viable, circulating endothelial cells in six colorectal cancer patient”
BackgroundJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., Crystal, R. G., Besmer, P., Lyden, D., Moore, M. A. S., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00754-7 · Cited by 1,751
Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09670-8 · Cited by 1,734
Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., Pilotti, S., Pierotti, M. A., & Daidone, M. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0626 · Cited by 1,723 · cited 1×
“Indeed, there is already a hint that the stem-cell subpopulation in breast cancer may be more adept at promoting angiogenesis than its non-stem-cell counterpar”
BackgroundBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,600
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration
Rafii, S., & Lyden, D. (2003) · Nature Medicine · doi:10.1038/nm0603-702 · Cited by 1,577
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536 · cited 1×
“They suggested that a key aspect of the cancer process is a disease of the vasculature in the whole area affected (reviewed in ref”
BackgroundSelf-citationClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517 · cited 1×
“These advances notwithstanding, much progress is needed on a variety of important issues; for example, how do we achieve the most effective combinations of antiangiogenic agents with chemotherapy or other biological agents and how do we select patients that are most likely to respond to the treatment? Another issue is…”
BackgroundSelf-citationIntegrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471 · cited 1×
“Further potential mechanisms of escape are integrin-signalling-mediated events, as there is growing evidence to support positive interactions between integrins and a variety of RTKs involved in tumour invasion, metastasis and angiogenesi”
BackgroundThe anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397 · cited 1×
“Because VEGF-A acts as a mobilizing and probably a survival agent for such cells, co-administration of a VEGF-targeting agent, especially one with a long half-life in the circulation (for example, anti-VEGF antibodies), would be expected to amplify and sustain the suppressive effects of standard (as well as metronomic…”
BackgroundSelf-citationBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“Withdrawal of VEGF-A leads to endothelial apoptosis and vascular regressio”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“An early phase III trial of advanced, heavily pretreated, metastatic breast cancer showed that adding bevacizumab to capecitabine chemotherapy did not improve progression-free survival, despite a doubling of the response rate (that is, tumour shrinkage of 50p or more) in the bevacizumab-treated arm of the tria”
BackgroundGlioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221 · cited 1×
“Tumour-growth inhibition has also been demonstrated using independent anti-VEGF approaches including a dominant-negative VEGFR-2 mutan”
MethodBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationCommon mechanisms of nerve and blood vessel wiring
Carmeliet, P., & Tessier-Lavigne, M. (2005) · Nature · doi:10.1038/nature03875 · Cited by 1,085
Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J. A., Hooper, A., Priller, J., De Klerck, B., et al. (2002) · Nature Medicine · doi:10.1038/nm731 · Cited by 1,068 · cited 1×
“However, there is growing evidence that VEGFR-1 has significant roles in haematopoiesis and in the recruitment of monocytes and other bone-marrow-derived cells that may home in on the tumour vasculature and promote angiogenesi”
BackgroundThe VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025 · cited 1×
“Although promising results were initially reported in small open-label trials, none of the placebo-controlled trials so far conducted with recombinant proteins or gene therapy has yielded convincingly positive result”
ResultEph receptor signalling casts a wide net on cell behaviour
Pasquale, E. B. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1662 · Cited by 1,017
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Self-citationHiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., & Shibuya, M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00153-8 · Cited by 910 · cited 1×
“In addition, VEGFR-1 is involved in the induction of matrix metalloproteinases (MMPs”
BackgroundWood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Self-citationRuckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
Gerber, H.-P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706
Self-citationRepopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686 · cited 1×
“Furthermore, it has been proposed that progressively accelerated proliferation and repopulation of cancer cells during intervals of radiotherapy or chemotherapy is an important cause of treatment failur”
BackgroundAngiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H.-P., Hillan, K. J., & Ferrara, N. (2003) · Science · doi:10.1126/science.1079562 · Cited by 679
Self-citationMorgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626 · cited 1×
“Subsequent studies have shown that many additional tumour cell lines, regardless of the tumour's origin, are inhibited in vivo by the same anti-VEGF monoclonal antibody (reviewed in ref”
BackgroundSelf-citationIdentification of an angiogenic mitogen selective for endocrine gland endothelium
LeCouter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Frantz, G., Rangell, L., DeGuzman, L., Keller, G.-A., et al. (2001) · Nature · doi:10.1038/35091000 · Cited by 555
Self-citationEndogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
De Palma, M., Venneri, M. A., Roca, C., & Naldini, L. (2003) · Nature Medicine · doi:10.1038/nm871 · Cited by 549
Lederman, R. J., Mendelsohn, F. O., Anderson, R. D., Saucedo, J. F., Tenaglia, A. N., Hermiller, J. B., Hillegass, W. B., Rocha-Singh, K., Moon, T. E., Whitehouse, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08937-7 · Cited by 511 · cited 1×
“Although promising results were initially reported in small open-label trials, none of the placebo-controlled trials so far conducted with recombinant proteins or gene therapy has yielded convincingly positive result”
ResultContribution of bone marrow–derived endothelial cells to human tumor vasculature
Peters, B. A., Diaz, L. A., Polyak, K., Meszler, L., Romans, K., Guinan, E. C., Antin, J. H., Myerson, D., Hamilton, S. R., Vogelstein, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1200 · Cited by 482
Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/6.1.73 · Cited by 472
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.030 · Cited by 471 · cited 1×
“However, more recent evidence indicates that, unexpectedly, Ang-2 has a positive role, at least in tumour angiogenesi”
BackgroundTumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470 · cited 1×
“described cytogenetical abnormalities in murine endothelial cells isolated from human tumour xenografts (aneuploidy, multiple abnormal centrosomes), although the mechanism for the acquisition of such alterations remains unknow”
BackgroundBertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Self-citationChen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448 · cited 1×
“75 ) and ranibizumab, a humanized high-affinity anti-VEGF Fab that neutralizes all VEGF-A isoforms and proteolytic fragment”
BackgroundEffect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Self-citationMacrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Angiogenesis: Where Do We Stand Now?
Simons, M. (2005) · Circulation · doi:10.1161/01.cir.0000159345.00591.8f · Cited by 411
Wang, B., Xiao, Y., Ding, B.-B., Zhang, N., Yuan, X.-B., Gui, L., Qian, K.-X., Duan, S., Chen, Z., Rao, Y., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00164-8 · Cited by 398
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Self-citationHIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318181 · Cited by 365
Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF-α-Induced Angiogenesis
Pandey, A., Shao, H., Marks, R. M., Polverini, P. J., & Dixit, V. M. (1995) · Science · doi:10.1126/science.7536959 · Cited by 363
HIF hydroxylation and the mammalian oxygen-sensing pathway
Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18181 · Cited by 363
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D. J., Ben-David, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.023 · Cited by 324
Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
Streubel, B., Chott, A., Huber, D., Exner, M., Jäger, U., Wagner, O., & Schwarzinger, I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033153 · Cited by 318 · cited 1×
“reported that a significant percentage of the endothelial cells in human B-cell lymphomas harbour lymphoma-specific chromosomal abnormalities, suggesting that endothelial cells in B-cell lymphomas may be in part tumour relate”
BackgroundVasohibin as an endothelium-derived negative feedback regulator of angiogenesis
Watanabe, K., Hasegawa, Y., Yamashita, H., Shimizu, K., Ding, Y., Abe, M., Ohta, H., Imagawa, K., Hojo, K., Maki, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421152 · Cited by 317 · cited 1×
“The most recently described endogenous inhibitor of angiogenesis is vasohibin, which seems to be derived from the endothelium and to operate as a feedback regulato”
BackgroundVascular‐targeting therapies for treatment of malignant disease
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2004) · Cancer · doi:10.1002/cncr.20299 · Cited by 310
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
Pike, S. E., Yao, L., Jones, K. D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2349 · Cited by 310
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
Self-citationPhase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O’Reilly, M. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.061 · Cited by 274 · cited 1×
“Recombinant human endostatin has been tested in phase I studies over the past few years to determine its safety and pharmacokinetic characteristics in patients with solid tumours, and these studies have documented a lack of dose-limiting toxicit”
BackgroundGerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Self-citationRuzinova, M. B., Schoer, R. A., Gerald, W., Egan, J. E., Pandolfi, P. P., Rafii, S., Manova, K., Mittal, V., & Benezra, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00240-x · Cited by 244
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237 · cited 1×
“Other possible mechanisms for acquired resistance to antiangiogenic drug”
BackgroundSelf-citationIde, A. (1939) · American Journal of Roentgenology · Cited by 234
A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis
Klagsbrun, M., & Eichmann, A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.002 · Cited by 221
Gasparini, G., Longo, R., Fanelli, M., & Teicher, B. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.022 · Cited by 200 · cited 1×
“Much preclinical evidence indicates that combining antiangiogenic agents with conventional cytotoxic agents or radiation therapy results in additive or even synergistic anti-tumour effect”
BackgroundWey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., et al. (2005) · Cancer · doi:10.1002/cncr.21145 · Cited by 194 · cited 1×
“Furthermore, in some cases VEGFR-1 is expressed by tumour cells and may mediate a chemotactic signal, thus potentially extending the role of this receptor in cancer growt”
BackgroundFunction of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors
Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., Benjamin, L. E., Lawler, J., Kieran, M., Shah, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500180102 · Cited by 179
Cancer Stem Cells: Are We Missing the Target?
Jones, R. J., Matsui, W. H., & Smith, B. D. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh095 · Cited by 169 · cited 1×
“It has been argued that this minor self-renewing subpopulation is absolutely crucial to progressive and sustained cancer growth, as opposed to the bulk non-stem-cell populatio”
BackgroundAntiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist
Dobrzanski, P., Hunter, K., Jones-Bolin, S., Chang, H., Robinson, C., Pritchard, S., Zhao, H., & Ruggeri, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3430-2 · Cited by 160
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
Brugarolas, J., & Kaelin, W. G. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.020 · Cited by 160 · cited 1×
“These genes include those associated with familial syndromes characterized by well-vascularized hamartoma”
BackgroundInhibition of Tumor Growth and Angiogenesis by Soluble EphB4
Martiny‐Baron, G., Korff, T., Schaffner, F., Esser, N., Eggstein, S., Marmé, D., & Augustin, H. G. (2004) · Neoplasia · doi:10.1593/neo.03457 · Cited by 132 · cited 1×
“Soluble EphB4-expressing human melanoma A375 cells grown subcutaneously in nude mice showed reduced tumour growth compared with control tumour”
MethodInhibition of Tumor Growth and Angiogenesis by Soluble EphB4
Martiny‐Baron, G., Korff, T., Schaffner, F., et al. (2004) · Neoplasia · doi:10.1593/neo.3457 · Cited by 117
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
GLADEBENDER, J., COONEY, E., KANDEL, J., & Yamashiro, D. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.001 · Cited by 99
Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy
Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 93
Samson, M., Peale, F. V., Jr., Frantz, G. D., Rioux-Leclercq, N. C., Meyts, E. R., & Ferrara, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032024 · Cited by 81 · cited 1×
“Highly vacularized endocrine malignancies such as Leydig cell tumours express particularly high levels of EG-VEGF mRN”
BackgroundSelf-citationThrombospondin as a regulator of angiogenesis
DiPietro, L. A. (1997) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-9006-9_12 · Cited by 54
Pathobiology of Ocular Disease
Katz, B. (1995) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199506000-00016 · Cited by 53
The efficacy of a ‘master switch gene’ HIF-1α in a porcine model of chronic myocardial ischaemia
Heinl-Green, A., Radke, P. W., Munkonge, F. M., Frass, O. M., Zhu, J., Vincent, K. A., Geddes, D. M., & Alton, E. W. F. W. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi223 · Cited by 47
Resistance in the anti-angiogenic era: nay-saying or a word of caution?
Sweeney, C. J., Miller, K. D., & Sledge, G. W. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)00007-2 · Cited by 42
Work on Breast Cancer Stem Cells Raises Questions About Treatment Strategies
Webb, T. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.774 · Cited by 4 · cited 1×
“It has been argued that this minor self-renewing subpopulation is absolutely crucial to progressive and sustained cancer growth, as opposed to the bulk non-stem-cell populatio”
Background
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,748
“Molecular cloning, however, revealed that these 2 proteins were identical and encoded by a single gene.(3) The VEGF family includes VEGF-A, VEGFB, VEGF-C, VEGF-D, PlGF (placental growth factor), VEGF-E (Orf-VEGF), and Trimeresurus flavoviridis svVEGF.”
BackgroundInfluentialHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
“The first good example of targeting an HIF-dependent gene product is the anti-VEGF-A therapeutic strateg”
BackgroundCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
“Vascular endothelial growth factor A (VEGFA) is best known for its effects on angiogenesi”
Background
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.